vs
MetroCity Bankshares, Inc.（MCBS）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是MetroCity Bankshares, Inc.的1.7倍（$75.5M vs $43.7M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 23.6%），MetroCity Bankshares, Inc.自由现金流更多（$37.0M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 15.7%）
MetroCity Bankshares, Inc.旗下的大都会城市银行是一家韩裔美国人创办的银行，总部位于佐治亚州多拉维尔，提供个人及商业银行服务。它是总部不在加利福尼亚州洛杉矶的最大韩美系银行，目前在德克萨斯、纽约、新泽西、弗吉尼亚、佐治亚、阿拉巴马和佛罗里达共设有19家分行。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
MCBS vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.7倍
$43.7M
营收增速更快
PBYI
高出4.1%
23.6%
自由现金流更多
MCBS
多$22.6M
$14.4M
两年增速更快
PBYI
近两年复合增速
15.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.7M | $75.5M |
| 净利润 | $18.1M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 52.8% | 22.7% |
| 净利率 | 50.5% | — |
| 营收同比 | 23.6% | 27.7% |
| 净利润同比 | 11.7% | — |
| 每股收益（稀释后） | $0.69 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCBSPBYI
| Q4 25 | $43.7M | $75.5M | ||
| Q3 25 | $38.0M | $54.5M | ||
| Q2 25 | $37.9M | $52.4M | ||
| Q1 25 | $36.0M | $46.0M | ||
| Q4 24 | $35.4M | $59.1M | ||
| Q3 24 | $36.9M | $80.5M | ||
| Q2 24 | $36.3M | $47.1M | ||
| Q1 24 | $32.7M | $43.8M |
净利润MCBSPBYI
| Q4 25 | $18.1M | — | ||
| Q3 25 | $17.3M | $8.8M | ||
| Q2 25 | $16.8M | $5.9M | ||
| Q1 25 | $16.3M | $3.0M | ||
| Q4 24 | $16.2M | — | ||
| Q3 24 | $16.7M | $20.3M | ||
| Q2 24 | $16.9M | $-4.5M | ||
| Q1 24 | $14.6M | $-4.8M |
毛利率MCBSPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率MCBSPBYI
| Q4 25 | 52.8% | 22.7% | ||
| Q3 25 | 62.8% | 17.6% | ||
| Q2 25 | 62.4% | 12.7% | ||
| Q1 25 | 61.3% | 8.7% | ||
| Q4 24 | 58.9% | 22.6% | ||
| Q3 24 | 61.4% | 27.4% | ||
| Q2 24 | 64.4% | -4.6% | ||
| Q1 24 | 62.6% | -5.3% |
净利率MCBSPBYI
| Q4 25 | 50.5% | — | ||
| Q3 25 | 45.5% | 16.2% | ||
| Q2 25 | 44.4% | 11.2% | ||
| Q1 25 | 45.3% | 6.5% | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 45.3% | 25.2% | ||
| Q2 24 | 46.7% | -9.6% | ||
| Q1 24 | 44.8% | -11.0% |
每股收益（稀释后）MCBSPBYI
| Q4 25 | $0.69 | $0.26 | ||
| Q3 25 | $0.67 | $0.17 | ||
| Q2 25 | $0.65 | $0.12 | ||
| Q1 25 | $0.63 | $0.06 | ||
| Q4 24 | $0.64 | $0.40 | ||
| Q3 24 | $0.65 | $0.41 | ||
| Q2 24 | $0.66 | $-0.09 | ||
| Q1 24 | $0.57 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.7M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $544.2M | $130.3M |
| 总资产 | $4.8B | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资MCBSPBYI
| Q4 25 | $383.7M | $97.5M | ||
| Q3 25 | $227.2M | $94.4M | ||
| Q2 25 | $286.0M | $96.0M | ||
| Q1 25 | $285.1M | $93.2M | ||
| Q4 24 | $249.9M | $101.0M | ||
| Q3 24 | $291.2M | $96.7M | ||
| Q2 24 | $327.9M | $96.8M | ||
| Q1 24 | $258.8M | $107.2M |
总债务MCBSPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益MCBSPBYI
| Q4 25 | $544.2M | $130.3M | ||
| Q3 25 | $445.9M | $115.3M | ||
| Q2 25 | $436.1M | $104.7M | ||
| Q1 25 | $428.0M | $97.1M | ||
| Q4 24 | $421.4M | $92.1M | ||
| Q3 24 | $407.2M | $71.1M | ||
| Q2 24 | $407.2M | $48.5M | ||
| Q1 24 | $396.6M | $51.0M |
总资产MCBSPBYI
| Q4 25 | $4.8B | $216.3M | ||
| Q3 25 | $3.6B | $202.9M | ||
| Q2 25 | $3.6B | $194.9M | ||
| Q1 25 | $3.7B | $196.2M | ||
| Q4 24 | $3.6B | $213.3M | ||
| Q3 24 | $3.6B | $220.7M | ||
| Q2 24 | $3.6B | $205.0M | ||
| Q1 24 | $3.6B | $214.1M |
负债/权益比MCBSPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.7M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $37.0M | $14.4M |
| 自由现金流率自由现金流/营收 | 84.7% | 19.1% |
| 资本支出强度资本支出/营收 | 1.5% | 0.0% |
| 现金转化率经营现金流/净利润 | 2.08× | — |
| 过去12个月自由现金流最近4个季度 | $79.4M | $41.7M |
8季度趋势，按日历期对齐
经营现金流MCBSPBYI
| Q4 25 | $37.7M | $14.4M | ||
| Q3 25 | $16.5M | $9.7M | ||
| Q2 25 | $14.5M | $14.1M | ||
| Q1 25 | $11.9M | $3.6M | ||
| Q4 24 | $63.5M | $15.6M | ||
| Q3 24 | $-11.5M | $11.0M | ||
| Q2 24 | $19.4M | $1.0M | ||
| Q1 24 | $36.4M | $11.2M |
自由现金流MCBSPBYI
| Q4 25 | $37.0M | $14.4M | ||
| Q3 25 | $16.2M | $9.7M | ||
| Q2 25 | $14.3M | $14.1M | ||
| Q1 25 | $11.8M | $3.6M | ||
| Q4 24 | $62.2M | $15.6M | ||
| Q3 24 | $-11.8M | $11.0M | ||
| Q2 24 | $19.0M | $1.0M | ||
| Q1 24 | $36.1M | — |
自由现金流率MCBSPBYI
| Q4 25 | 84.7% | 19.1% | ||
| Q3 25 | 42.7% | 17.7% | ||
| Q2 25 | 37.8% | 26.8% | ||
| Q1 25 | 32.9% | 7.7% | ||
| Q4 24 | 175.8% | 26.4% | ||
| Q3 24 | -31.9% | 13.7% | ||
| Q2 24 | 52.4% | 2.1% | ||
| Q1 24 | 110.6% | — |
资本支出强度MCBSPBYI
| Q4 25 | 1.5% | 0.0% | ||
| Q3 25 | 0.7% | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 3.6% | 0.0% | ||
| Q3 24 | 0.8% | 0.0% | ||
| Q2 24 | 1.0% | 0.0% | ||
| Q1 24 | 0.7% | 0.0% |
现金转化率MCBSPBYI
| Q4 25 | 2.08× | — | ||
| Q3 25 | 0.95× | 1.10× | ||
| Q2 25 | 0.86× | 2.41× | ||
| Q1 25 | 0.73× | 1.21× | ||
| Q4 24 | 3.91× | — | ||
| Q3 24 | -0.69× | 0.54× | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 2.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
